SAN DIEGO, April 30, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Deutsche Bank 39th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, May 7, 2014, in Boston.
An audio webcast and a copy of the presentation will be available live and archived in the Investor Center of the company's website at www.conatuspharma.com.
About Conatus Pharmaceuticals Inc.
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing emricasan as a first-in class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease. For additional information, please visit www.conatuspharma.com.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release, including statements regarding anticipated clinical development plans and proposed activity of emricasan in patients with liver disease, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including: changes in the planned use of proceeds from Conatus' initial public offering; Conatus' ability to maintain sufficient capital to advance the clinical development of emricasan and fund Conatus' operations; Conatus' reliance on third parties to conduct its clinical trials, manufacture its preclinical and clinical drug supplies and manufacture commercial supplies of emricasan, if approved; potential adverse side effects or other safety risks associated with emricasan; results of current and future clinical trials of emricasan; the uncertainty of the FDA approval process and other regulatory requirements; the potential for competing products to limit the clinical trial enrollment opportunities for emricasan in certain indications; and those described in Conatus' prior press releases and the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in Conatus' forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Conatus does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT: INVESTORS Alan Engbring, Conatus Pharmaceuticals (858) 457-7237, firstname.lastname@example.org MEDIA Mariesa Kemble, Sam Brown Inc. (608) 850-4745, email@example.comSource:Conatus Pharmaceuticals